Publications

• Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

  (Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS.) JAMA Oncol. 2021 Jul 01;7(7):993-1003 PMID: 33956047 PMCID: PMC8283558 SCOPUS ID: 2-s2.0-85105866863 05/07/2021

• National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.

  (Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J.) J Clin Oncol. 2021 Jun 20;39(18):1971-1982 PMID: 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 04/28/2021

• Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

  (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2021 Jun 18 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021

• Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis.

  (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M.) Blood Cancer J. 2021 Apr 29;11(4):82 PMID: 33927193 PMCID: PMC8085088 SCOPUS ID: 2-s2.0-85105142269 05/01/2021

• PD-1 blockade after bispecific LV20.19 CAR-T modulates CAR T-cell immunophenotype without meaningful clinical response.

  (Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN.) Haematologica. 2021 Apr 15 PMID: 33853295 04/16/2021

• Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?

  (Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M.) Blood. 2021 03 11;137(10):1416-1423 PMID: 33120429 PMCID: PMC7955408 SCOPUS ID: 2-s2.0-85102604135 10/30/2020

• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

  (Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M.) Lancet. 2021 Mar 06;397(10277):892-901 PMID: 33676628 SCOPUS ID: 2-s2.0-85101887008 03/08/2021

• Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

  (Shah NN, Hamadani M.) J Clin Oncol. 2021 02 10;39(5):487-498 PMID: 33434076 SCOPUS ID: 2-s2.0-85102044262 01/13/2021

• Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005))

  (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85101258094 01/01/2021

• Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

  (Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P, GIMEMA, European Research Initiative (ERIC) on CLL, US study group.) Cancer Med. 2020 11;9(22):8468-8479 PMID: 32969597 PMCID: PMC7666748 SCOPUS ID: 2-s2.0-85091352623 09/25/2020

• Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

  (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020

• The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.

  (Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M.) Blood Lymphat Cancer. 2020;10:1-5 PMID: 32943973 PMCID: PMC7473982 09/19/2020